Parkinson’s Disease :: Parkinson’s drug rotigotine shows promise

Research led by a team from UAB (University of Alabama at Birmingham) has shown that a dopamine agonist called rotigotine could be effective in treating symptoms of Parkinson?s disease (PD). In a study published Jan. 3 in the online edition of Neurology, rotigotine significantly improved symptoms in patients with early-stage PD.

PD is characterized by a shortage of a neurotransmitter in the brain called dopamine. Without suitable amounts of dopamine, PD patients are unable to control their movements reliably. Rotigotine, manufactured by Schwarz Pharma, is a dopamine agonist ? a drug that mimics the action of dopamine in the brain and compensates for the shortage.

The multi-center study evaluated the safety and effectiveness of once-daily rotigotine, delivered continuously through the skin via a patch, versus placebo in patients with early-stage PD.

?This study showed that rotigotine may be safe and effective, and potentially be of major value in the treatment of early-stage PD,? said Ray. L. Watts, M.D., chair of the UAB Department of Neurology and principal investigator of the study. ?Parkinson?s disease is a progressive disorder and rotigotine seems to offset the variability we often see in the multiple dose regimens of other drugs used to treat PD.?


Do NOT follow this link or you will be banned from the site!